|
1
|
Uribe ML, Marrocco I and Yarden Y: EGFR in
cancer: Signaling mechanisms, drugs, and acquired resistance.
Cancers (Basel). 13(2748)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Koulouris A, Tsagkaris C, Corriero AC,
Metro G and Mountzios G: Resistance to TKIs in EGFR-mutated
non-small cell lung cancer: From mechanisms to new therapeutic
strategies. Cancers (Basel). 14(3337)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Li A, Cao W, Liu X, Zhang Y, Ma Y, Xu R,
Zhang R, Liu X, Zhou S, Wang R, et al: Gefitinib sensitization of
cisplatin-resistant wild-type EGFR non-small cell lung cancer
cells. J Cancer Res Clin Oncol. 146:1737–1749. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nishihara S, Yamaoka T, Ishikawa F,
Higuchi K, Hasebe Y, Manabe R, Kishino Y, Kusumoto S, Ando K,
Kuroda Y, et al: Mechanisms of EGFR-TKI-induced apoptosis and
strategies targeting apoptosis in EGFR-mutated non-small cell lung
cancer. Genes (Basel). 13(2183)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tanaka K, Yu HA, Yang S, Han S, Selcuklu
SD, Kim K, Ramani S, Ganesan YT, Moyer A, Sinha S, et al: Targeting
Aurora B kinase prevents and overcomes resistance to EGFR
inhibitors in lung cancer by enhancing BIM- and PUMA-mediated
apoptosis. Cancer Cell. 39:1245–1261.e6. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shimizu T, Nishio K, Sakai K, Okamoto I,
Okamoto K, Takeda M, Morishita M and Nakagawa K: Phase I safety and
pharmacokinetic study of YM155, a potent selective survivin
inhibitor, in combination with erlotinib in patients with EGFR TKI
refractory advanced non-small cell lung cancer. Cancer Chemother
Pharmacol. 86:211–219. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Allen T, van Tuyl M, Iyengar P, Jothy S,
Post M, Tsao MS and Lobe CG: Grg1 acts as a lung-specific oncogene
in a transgenic mouse model. Cancer Res. 66:1294–1301.
2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yao X, Ireland SK, Pham T, Temple B, Chen
R, Raj MH and Biliran H: TLE1 promotes EMT in A549 lung cancer
cells through suppression of E-cadherin. Biochem Biophys Res
Commun. 455:277–284. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yao X, Pham T, Temple B, Gray S, Cannon C,
Hardy C, Fletcher K, Ireland SK, Hossain A, Chen R, et al: TLE1
inhibits anoikis and promotes tumorigenicity in human lung cancer
cells through ZEB1-mediated E-cadherin repression. Oncotarget.
8:72235–72249. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition
derived from repeated exposure to gefitinib determines the
sensitivity to EGFR inhibitors in A549, a non-small cell lung
cancer cell line. Lung Cancer. 63:219–226. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X,
Ding W, Ouyang S, Lu J, Yue P, et al: Metabolic reprogramming
driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors
in non-small cell lung cancer. Cancer Res. 83:2187–2207.
2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Périer RC, Praz V, Junier T, Bonnard C and
Bucher P: The eukaryotic promoter database (EPD). Nucleic Acids
Res. 28:302–303. 2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhu X, Chen L, Liu L and Niu X:
EMT-mediated acquired EGFR-TKI resistance in NSCLC: Mechanisms and
strategies. Front Oncol. 9(1044)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH,
Kim CH and Lee JC: p53 enhances gefitinib-induced growth inhibition
and apoptosis by regulation of Fas in non-small cell lung cancer.
Cancer Res. 67:1163–1169. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Witta SE, Gemmill RM, Hirsch FR, Coldren
CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita
M, et al: Restoring E-cadherin expression increases sensitivity to
epidermal growth factor receptor inhibitors in lung cancer cell
lines. Cancer Res. 66:944–950. 2006.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zheng Q, Dong H, Mo J, Zhang Y, Huang J,
Ouyang S, Shi S, Zhu K, Qu X, Hu W, et al: A novel STAT3 inhibitor
W2014-S regresses human non-small cell lung cancer xenografts and
sensitizes EGFR-TKI acquired resistance. Theranostics. 11:824–840.
2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Si J, Ma Y, Lv C, Hong Y, Tan H and Yang
Y: HIF1A-AS2 induces osimertinib resistance in lung adenocarcinoma
patients by regulating the miR-146b-5p/IL-6/STAT3 axis. Mol Ther
Nucleic Acids. 26:613–624. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Liang J, Bi G, Sui Q, Zhao G, Zhang H,
Bian Y, Chen Z, Huang Y, Xi J, Shi Y, et al: Transcription factor
ZNF263 enhances EGFR-targeted therapeutic response and reduces
residual disease in lung adenocarcinoma. Cell Rep.
43(113771)2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Qin Q, Li X, Liang X, Zeng L, Wang J, Sun
L and Zhong D: Targeting the EMT transcription factor Snail
overcomes resistance to osimertinib in EGFR-mutant non-small cell
lung cancer. Thorac Cancer. 12:1708–1715. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Brunquell C, Biliran H, Jennings S,
Ireland SK, Chen R and Ruoslahti E: TLE1 is an anoikis regulator
and is downregulated by Bit1 in breast cancer cells. Mol Cancer
Res. 10:1482–1495. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yao X, Pham T, Temple B, Gray S, Cannon C,
Chen R, Abdel-Mageed AB and Biliran H: The anoikis effector bit1
inhibits emt through attenuation of TLE1-mediated repression of
E-cadherin in lung cancer cells. PLoS One.
11(e0163228)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bovan D, Krajnović T, Vuković NL, Vukić
MD, Mijatović S, Tanić N, Arsenijević N and Maksimović-Ivanić D:
Anoikis and cancer cell differentiation: Novel modes of shikonin
derivatives anticancer action in vitro. Mol Biol Rep.
51(218)2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sasaki CY, Lin HC and Passaniti A:
Expression of E-cadherin reduces bcl-2 expression and increases
sensitivity to etoposide-induced apoptosis. Int J Cancer.
86:660–666. 2000.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lee AF, Chen MC, Chen CJ, Yang CJ, Huang
MS and Liu YP: Reverse epithelial-mesenchymal transition
contributes to the regain of drug sensitivity in tyrosine kinase
inhibitor-resistant non-small cell lung cancer cells. PLoS One.
12(e0180383)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gohlke L, Alahdab A, Oberhofer A, Worf K,
Holdenrieder S, Michaelis M, Cinatl J Jr and Ritter CA: Loss of key
EMT-regulating miRNAs highlight the role of ZEB1 in EGFR tyrosine
kinase inhibitor-resistant NSCLC. Int J Mol Sci.
24(14742)2023.PubMed/NCBI View Article : Google Scholar
|
